Key result
MicroRNA therapeutics show emerging potential across cardiovascular disease despite ongoing translational challenges.
The discovery of microRNAs and their role in diseases was a breakthrough that inspired research into microRNAs as drug targets. Cardiovascular diseases are an area in which limitations of conventional pharmacotherapy are highly apparent and where microRNA-based drugs have appreciably progressed into preclinical and clinical testing. In this Review, we summarize the current state of microRNAs as therapeutic targets in the cardiovascular system. We report recent advances in the identification and characterization of microRNAs, their manipulation and clinical translation, and discuss challenges and perspectives toward clinical application.
No takes yet. Share an insight, caveat, or question.
Laggerbauer et al. (2022) conducted a review in Cardiovascular disease. MicroRNA-based drugs was evaluated. MicroRNAs are emerging as potential therapeutic targets for cardiovascular diseases, with recent progress in preclinical and clinical testing despite current translational challenges.
Synapse has enriched 5 related papers. Consider them for comparative context: